Antihypertensive Therapie beim metabolischen Syndrom

Translated title of the contribution: Antihypertensive therapy in patients with the metabolic syndrome

S. Jacob, Erik J Henriksen, H. J. Augustin, G. J. Dietze

Research output: Contribution to journalArticle

Abstract

In the metabolic syndrome with hypertension, dyslipidemia, obesity, and glucose intolerance, insulin resistance and compensatory hyperinsulinemia are thought to play a central role. Retrospective epidemiological data indicate a lower than expected reduction of coronary events, although blood pressure had been effectively controlled. Neglect of concomitant risk factors, and a further deterioration of these cardiovascular risk factors through the type of antihypertensive intervention used seem to have contributed to this 'coronary paradox'. Recently, glucose clamp studies showed that diuretics and betablockers reduce insulin sensitivity and worsen dyslipidemia; these effects were reversible after the drugs were discontinued. Calcium channel blockers seem to be metabolically neutral, while ACE-inhibitors, vasodilating betablockers, α1-inhibitors and moxonidine even improve hyperlipidemia and insulin resistance. Thus, antihypertensive agents which further increase the known cardiovascular risk factors, should not be considered as drugs of first choice in hypertensive patients with the metabolic syndrome. Although, up to now, no long-term morbidity study is available to prove superiority of these newer agents, we believe that it would be wrong to withhold a modern, risk factor-adapted antihypertensive treatment from patients with the metabolic syndrome.

Original languageGerman
Pages (from-to)764-769
Number of pages6
JournalMunchener Medizinische Wochenschrift
Volume138
Issue number46
StatePublished - 1996
Externally publishedYes

Fingerprint

Antihypertensive Agents
Insulin Resistance
moxonidine
Dyslipidemias
Glucose Clamp Technique
Glucose Intolerance
Calcium Channel Blockers
Hyperinsulinism
Therapeutics
Hyperlipidemias
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Pharmaceutical Preparations
Obesity
Blood Pressure
Hypertension
Morbidity

Keywords

  • antihypertensive agents
  • dyslipidemia
  • glucose metabolism
  • insulin resistance
  • metabolic syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jacob, S., Henriksen, E. J., Augustin, H. J., & Dietze, G. J. (1996). Antihypertensive Therapie beim metabolischen Syndrom. Munchener Medizinische Wochenschrift, 138(46), 764-769.

Antihypertensive Therapie beim metabolischen Syndrom. / Jacob, S.; Henriksen, Erik J; Augustin, H. J.; Dietze, G. J.

In: Munchener Medizinische Wochenschrift, Vol. 138, No. 46, 1996, p. 764-769.

Research output: Contribution to journalArticle

Jacob, S, Henriksen, EJ, Augustin, HJ & Dietze, GJ 1996, 'Antihypertensive Therapie beim metabolischen Syndrom', Munchener Medizinische Wochenschrift, vol. 138, no. 46, pp. 764-769.
Jacob, S. ; Henriksen, Erik J ; Augustin, H. J. ; Dietze, G. J. / Antihypertensive Therapie beim metabolischen Syndrom. In: Munchener Medizinische Wochenschrift. 1996 ; Vol. 138, No. 46. pp. 764-769.
@article{c8d8a971fa6943b382e2213e71875867,
title = "Antihypertensive Therapie beim metabolischen Syndrom",
abstract = "In the metabolic syndrome with hypertension, dyslipidemia, obesity, and glucose intolerance, insulin resistance and compensatory hyperinsulinemia are thought to play a central role. Retrospective epidemiological data indicate a lower than expected reduction of coronary events, although blood pressure had been effectively controlled. Neglect of concomitant risk factors, and a further deterioration of these cardiovascular risk factors through the type of antihypertensive intervention used seem to have contributed to this 'coronary paradox'. Recently, glucose clamp studies showed that diuretics and betablockers reduce insulin sensitivity and worsen dyslipidemia; these effects were reversible after the drugs were discontinued. Calcium channel blockers seem to be metabolically neutral, while ACE-inhibitors, vasodilating betablockers, α1-inhibitors and moxonidine even improve hyperlipidemia and insulin resistance. Thus, antihypertensive agents which further increase the known cardiovascular risk factors, should not be considered as drugs of first choice in hypertensive patients with the metabolic syndrome. Although, up to now, no long-term morbidity study is available to prove superiority of these newer agents, we believe that it would be wrong to withhold a modern, risk factor-adapted antihypertensive treatment from patients with the metabolic syndrome.",
keywords = "antihypertensive agents, dyslipidemia, glucose metabolism, insulin resistance, metabolic syndrome",
author = "S. Jacob and Henriksen, {Erik J} and Augustin, {H. J.} and Dietze, {G. J.}",
year = "1996",
language = "German",
volume = "138",
pages = "764--769",
journal = "MMW Fortschritte der Medizin",
issn = "1438-3276",
publisher = "Urban und Vogel",
number = "46",

}

TY - JOUR

T1 - Antihypertensive Therapie beim metabolischen Syndrom

AU - Jacob, S.

AU - Henriksen, Erik J

AU - Augustin, H. J.

AU - Dietze, G. J.

PY - 1996

Y1 - 1996

N2 - In the metabolic syndrome with hypertension, dyslipidemia, obesity, and glucose intolerance, insulin resistance and compensatory hyperinsulinemia are thought to play a central role. Retrospective epidemiological data indicate a lower than expected reduction of coronary events, although blood pressure had been effectively controlled. Neglect of concomitant risk factors, and a further deterioration of these cardiovascular risk factors through the type of antihypertensive intervention used seem to have contributed to this 'coronary paradox'. Recently, glucose clamp studies showed that diuretics and betablockers reduce insulin sensitivity and worsen dyslipidemia; these effects were reversible after the drugs were discontinued. Calcium channel blockers seem to be metabolically neutral, while ACE-inhibitors, vasodilating betablockers, α1-inhibitors and moxonidine even improve hyperlipidemia and insulin resistance. Thus, antihypertensive agents which further increase the known cardiovascular risk factors, should not be considered as drugs of first choice in hypertensive patients with the metabolic syndrome. Although, up to now, no long-term morbidity study is available to prove superiority of these newer agents, we believe that it would be wrong to withhold a modern, risk factor-adapted antihypertensive treatment from patients with the metabolic syndrome.

AB - In the metabolic syndrome with hypertension, dyslipidemia, obesity, and glucose intolerance, insulin resistance and compensatory hyperinsulinemia are thought to play a central role. Retrospective epidemiological data indicate a lower than expected reduction of coronary events, although blood pressure had been effectively controlled. Neglect of concomitant risk factors, and a further deterioration of these cardiovascular risk factors through the type of antihypertensive intervention used seem to have contributed to this 'coronary paradox'. Recently, glucose clamp studies showed that diuretics and betablockers reduce insulin sensitivity and worsen dyslipidemia; these effects were reversible after the drugs were discontinued. Calcium channel blockers seem to be metabolically neutral, while ACE-inhibitors, vasodilating betablockers, α1-inhibitors and moxonidine even improve hyperlipidemia and insulin resistance. Thus, antihypertensive agents which further increase the known cardiovascular risk factors, should not be considered as drugs of first choice in hypertensive patients with the metabolic syndrome. Although, up to now, no long-term morbidity study is available to prove superiority of these newer agents, we believe that it would be wrong to withhold a modern, risk factor-adapted antihypertensive treatment from patients with the metabolic syndrome.

KW - antihypertensive agents

KW - dyslipidemia

KW - glucose metabolism

KW - insulin resistance

KW - metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=0029862072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029862072&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029862072

VL - 138

SP - 764

EP - 769

JO - MMW Fortschritte der Medizin

JF - MMW Fortschritte der Medizin

SN - 1438-3276

IS - 46

ER -